Investor Relations (IR) Questions: Genspera Inc $GNSZ
Click here to return to the biotech IRQ Index
Answers compiled: May 2013
-1- When is the last time GNSZ raised cash through an offering (diluted)?
-a- In December 2012 the Company initiated an offering raising $881,000 in gross proceeds. The sale originally consisted of 400,461 shares and one warrant per share individually priced at $2.20. Warrants are good for five years from the closing date at an exercise price of $3.00 per warrant. However, In March 2013 the Company issued an additional 96,443 shares and warrants effectively bringing the per share and warrant price down to $1.773. The exercise price of warrants did not change.
-a- In March 2013 the Company sold an additional 557,256 shares/warrants in connection with the December 2012 offering. Gross proceeds were $988,000. The terms of the offering were “substantially the same form as the Investors in the December Offering...”. Shares/warrants were individually priced at $1.773.
-a- “To date, the Company has issued 1,054,160 units, 18,410 PA Warrants and received gross proceeds of $1,869,000 in connection with the December Offering.”
-2- How much cash (not cash equivalents) does GNSZ have?
-b- Cash and cash equivalents were reported at $2,553,000 as of 03/31/2013.
-3- What and approximately when is the next known catalyst?
-c- G-202 PHASE II: The Company expects interim data in Q3 2013. The last patient is expected to enroll in Q1 2014.
-d- G-202 PHASE II Pca: The Company expects interim data in Q3 2013. The last patient is expected to enroll in Q1 2014.
-4- What is GNSZ's quarterly cash burn?
-e- Total Operating Expenses for the period covering the first three months of 2013 were $1,531,000. Total Operating Expenses for the same period in 2012 were $1,405,000.
-f- The Company believes that it has sufficient resources to continue operating through September, 2013.
-5- Does GNSZ have an existing line of credit and if so how much can they draw against it?
Upon reviewing the Company's most recent Form 10-Q, I did not find any reference to an existing line of credit or credit facility. I do not believe one exists. However, for absolute conformation, I recommend contacting the Company.
ADDITIONAL POINT(S) OF INTEREST:
-g- On August 6, 2012, the Company announced the appointment of Nancy Jean Barnabei to the position Vice President Finance and Treasurer.
-h- On May 6, 2013, the Company received Nancy Jean Barnabei's resignation. The resignation was not the result of a disagreement with the Company which "expects to fulfill its accounting and reporting requirements through an accounting consultant".
A complete archive of this research along with other IRQ research and IR responses can be found at http://www.biotechduediligence.com/ir-questions.html
RESOURCES:
-a- GNSZ Form 8-K filed 03/28/2013 http://biz.yahoo.com/e/130328/gnsz8-k.html
-b- Page 4, GNSZ Form 10-Q for the period ending 03/31/2013http://gnsz.ir.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingCONVPDF1?SessionID=34aU6r2-IccVzpS&ID=9283580
-c- Slide 10, GNSZ 11/2012 Presentation http://www.genspera.com/investors/121129_GenSpera_NYSSA_Pres_112912.pdf
-d- Slide 11, GNSZ 11/2012 Presentation http://www.genspera.com/investors/121129_GenSpera_NYSSA_Pres_112912.pdf
-e- Page 5, GNSZ Form 10-Q for the period ending 03/31/2013http://gnsz.ir.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingCONVPDF1?SessionID=34aU6r2-IccVzpS&ID=9283580
-f- Page 15, GNSZ Form 10-Q for the period ending 03/31/2013http://gnsz.ir.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingCONVPDF1?SessionID=34aU6r2-IccVzpS&ID=9283580
-g- GNSZ PR dated 09/21/2012: http://www.genspera.com/press/120821_Finance_VP_Release.pdf
-h- Page 13, GNSZ Form 10-Q for the period ending 03/31/2013http://gnsz.ir.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingCONVPDF1?SessionID=34aU6r2-IccVzpS&ID=9283580
-1- When is the last time GNSZ raised cash through an offering (diluted)?
-a- In December 2012 the Company initiated an offering raising $881,000 in gross proceeds. The sale originally consisted of 400,461 shares and one warrant per share individually priced at $2.20. Warrants are good for five years from the closing date at an exercise price of $3.00 per warrant. However, In March 2013 the Company issued an additional 96,443 shares and warrants effectively bringing the per share and warrant price down to $1.773. The exercise price of warrants did not change.
-a- In March 2013 the Company sold an additional 557,256 shares/warrants in connection with the December 2012 offering. Gross proceeds were $988,000. The terms of the offering were “substantially the same form as the Investors in the December Offering...”. Shares/warrants were individually priced at $1.773.
-a- “To date, the Company has issued 1,054,160 units, 18,410 PA Warrants and received gross proceeds of $1,869,000 in connection with the December Offering.”
-2- How much cash (not cash equivalents) does GNSZ have?
-b- Cash and cash equivalents were reported at $2,553,000 as of 03/31/2013.
-3- What and approximately when is the next known catalyst?
-c- G-202 PHASE II: The Company expects interim data in Q3 2013. The last patient is expected to enroll in Q1 2014.
-d- G-202 PHASE II Pca: The Company expects interim data in Q3 2013. The last patient is expected to enroll in Q1 2014.
-4- What is GNSZ's quarterly cash burn?
-e- Total Operating Expenses for the period covering the first three months of 2013 were $1,531,000. Total Operating Expenses for the same period in 2012 were $1,405,000.
-f- The Company believes that it has sufficient resources to continue operating through September, 2013.
-5- Does GNSZ have an existing line of credit and if so how much can they draw against it?
Upon reviewing the Company's most recent Form 10-Q, I did not find any reference to an existing line of credit or credit facility. I do not believe one exists. However, for absolute conformation, I recommend contacting the Company.
ADDITIONAL POINT(S) OF INTEREST:
-g- On August 6, 2012, the Company announced the appointment of Nancy Jean Barnabei to the position Vice President Finance and Treasurer.
-h- On May 6, 2013, the Company received Nancy Jean Barnabei's resignation. The resignation was not the result of a disagreement with the Company which "expects to fulfill its accounting and reporting requirements through an accounting consultant".
A complete archive of this research along with other IRQ research and IR responses can be found at http://www.biotechduediligence.com/ir-questions.html
RESOURCES:
-a- GNSZ Form 8-K filed 03/28/2013 http://biz.yahoo.com/e/130328/gnsz8-k.html
-b- Page 4, GNSZ Form 10-Q for the period ending 03/31/2013http://gnsz.ir.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingCONVPDF1?SessionID=34aU6r2-IccVzpS&ID=9283580
-c- Slide 10, GNSZ 11/2012 Presentation http://www.genspera.com/investors/121129_GenSpera_NYSSA_Pres_112912.pdf
-d- Slide 11, GNSZ 11/2012 Presentation http://www.genspera.com/investors/121129_GenSpera_NYSSA_Pres_112912.pdf
-e- Page 5, GNSZ Form 10-Q for the period ending 03/31/2013http://gnsz.ir.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingCONVPDF1?SessionID=34aU6r2-IccVzpS&ID=9283580
-f- Page 15, GNSZ Form 10-Q for the period ending 03/31/2013http://gnsz.ir.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingCONVPDF1?SessionID=34aU6r2-IccVzpS&ID=9283580
-g- GNSZ PR dated 09/21/2012: http://www.genspera.com/press/120821_Finance_VP_Release.pdf
-h- Page 13, GNSZ Form 10-Q for the period ending 03/31/2013http://gnsz.ir.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingCONVPDF1?SessionID=34aU6r2-IccVzpS&ID=9283580
